Sai Life Sciences Q2 FY26: EBITDA Up 43%, Profit Doubles

What Sai Life Sciences reported for Q2 and H1 FY26

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE) announced its financial results for the second quarter and half year ended September 2025. The company reported year-on-year growth of 36% in revenue and 43% in EBITDA for the period. Net profit rose 100% over the same timeframe, according to the update shared from Hyderabad on November 06, 2025. While the release highlighted percentage growth, it did not specify the absolute quarterly revenue or profit figures in the provided text. The performance was positioned as outpacing broader industry trends. Sai Life Sciences also described its business as tracking ahead of plan.

A CRDMO profile built around integrated services

Sai Life Sciences operates as a Contract Research, Development and Manufacturing Organization (CRDMO), spanning drug discovery, development, and API manufacturing. The company described itself as working closely with global pharma innovators, reflecting the wider shift toward outsourcing complex scientific and manufacturing work. The text also frames Sai’s journey as a transition from a smaller-scale CRO to an integrated CRDMO, with operational scaling alongside financial growth. Management commentary in the provided material pointed to increasing strategic conversations with large global pharma companies. These conversations were linked to resilience-focused supply chains, specialized capabilities, and long-term partnerships.

Why outsourcing demand is rising and why India matters

The provided material ties growth opportunities to several structural trends. It cites increasing R&D costs globally and a broader push for integrated service providers. A recurring driver is the China+1 strategy, where pharma companies diversify supply chains away from single-country dependence. The macro environment was described as supportive, with India “increasingly positioned as a preferred destination for pharmaceutical outsourcing.” The text also describes a “global supply-chain rebalancing” underway.

CRO segment: focus on large pharma engagement

Sai Life Sciences said it is seeing sustained growth momentum in its CRO segment. The stated driver is a focus on expanding engagements with large pharma customers. The update does not provide segment-level numbers, but it indicates that the CRO business is being used to deepen relationships with larger clients. The company also pointed to continued momentum in the development segment, with global customers transitioning R&D FTEs and development activities to India. According to the text, this shift has led to an uptick in revenues “this year” and is creating a steady pipeline of downstream opportunities.

CDMO segment: concentration in large pharma clients

On the CDMO side, the company said business continues to perform well. It stated that over 90% of CDMO revenues come from large pharma customers. The material also links the development pipeline to manufacturing opportunities, suggesting progression from earlier-stage work to later-stage and manufacturing engagements. It further notes that, over time, this trend is expected to improve the company’s overall material margin profile, though no margin numbers were provided.

Capital expenditure and scaling: investment and hiring plan

The provided text describes Sai Life Sciences as being in a high-growth phase with a large step-up in capital expenditure aimed at capturing shifts in global supply chains. One passage states the company invested more than $119 million over the last six years to expand manufacturing. Another passage states that in FY25, the company invested ₹408 crore in capital expenditure to enhance its manufacturing footprint and discovery capabilities.

Separately, an update from Mumbai stated the company plans to raise headcount by more than 700 people, or about 20%, in the next financial year as it scales up capacity to meet rising global demand. The expansion was described as being primarily in Hyderabad, where the company’s largest R&D center is expected to support advanced drug development, data-enabled discovery, and commercial manufacturing scale-up.

Key reported metrics and data points

The text includes a mix of quarterly growth indicators, annual numbers, and market context. Where absolute financials are stated, they are reported below as provided.

Market forecasts cited in the text

The provided material includes multiple growth estimates for the contract research and manufacturing opportunity.

Stock context and investor commentary included

The text notes that the stock listed in December 2024 at ₹636 and was “already up 48% from IPO lows.” It also includes an external-style return expectation (“5-Year Return Estimate: 18–25% CAGR | 10-Year: 15–20% CAGR”). These return estimates are not presented as company guidance in the provided material, and no basis or methodology is included alongside them. The content also says the company’s valuation is not a “screaming bargain,” while arguing that investors are paying for a quality CRDMO exposure. Readers should treat such statements as commentary rather than audited financial disclosure.

Why this update matters for investors tracking Indian CRDMOs

The update combines near-term financial acceleration with longer-term capacity building. The reported Q2 and H1 percentage growth suggests operating momentum during a period when global pharma companies are rebalancing supply chains. Client concentration toward large pharma, as indicated by the 90%+ CDMO revenue mix, can be relevant for volume stability and visibility, as implied in the text. At the same time, the scaling plan, including capex and 700+ planned hires, indicates higher operating intensity and execution focus in the coming year.

Conclusion

Sai Life Sciences’ September 2025 quarter update highlighted strong year-on-year growth in revenue, EBITDA, and net profit, alongside management commentary pointing to sustained demand from large global pharma customers. The company is also scaling its manufacturing and development capabilities through capex and a planned headcount increase, with Hyderabad positioned as a major hub. The next key milestones to track, based on the provided text, are execution of the hiring and capacity expansion plans and continued conversion of development pipeline into manufacturing opportunities.